RNK08954:高选择性口服KRASG12D抑制剂的临床前特征与临床活性
RNK08954是一种强效选择性口服KRASG12D抑制剂,临床前可抑制KRASG12D突变细胞增殖并使小鼠移植瘤显著消退,其独特药代动力学特征延长了肿瘤组织滞留时间,并与免疫检查点阻断协同。Ia期研究中36例可评估患者中位随访4.85个月,NSCLC客观缓解率(未确认)58.33%,PDAC在1000-1200mg队列客观缓解率(未确认)33.33%。
要点
- RNK08954是潜在首个口服生物利用KRASG12D抑制剂,临床前显示显著抗肿瘤活性。
- Ia期NSCLC未确认ORR为58.33%,PDAC 1000-1200mg队列未确认ORR为33.33%。
- 临床前与免疫检查点阻断联用显示协同作用,支持单药或联合临床开发。
核心结论
- RNK08954在KRASG12D突变患者中单药或联合治疗均具临床潜力。
- RNK08954可能填补跨实体瘤最常见KRAS突变亚型的治疗空白。
研究设计与样本
- 临床前研究评估RNK08954对KRASG12D突变细胞的增殖抑制及小鼠移植瘤模型疗效。
- Ia期研究纳入36例可评估患者,中位随访4.85个月。
主要发现
- RNK08954抑制KRASG12D突变细胞增殖并抑制KRAS介导信号,小鼠移植瘤显著消退。
- 其体内效应由独特药代动力学特征及肿瘤组织显著延长滞留时间解释。
- 临床前显示与免疫检查点阻断协同。
- NSCLC患者客观缓解率(未确认)为58.33%。
- PDAC患者1000-1200mg队列客观缓解率(未确认)为33.33%。
关键数值与推荐
- NSCLC客观缓解率(未确认)58.33%。
- PDAC 1000-1200mg队列客观缓解率(未确认)33.33%。
- 36例可评估患者中位随访4.85个月。
临床怎么用
- 针对KRASG12D突变实体瘤可考虑RNK08954单药或联合免疫检查点阻断。
- NSCLC与PDAC为初步显示活性的瘤种,需进一步临床验证。
局限性
- Ia期数据为初步结果,缓解率未确认,随访时间较短。
- 可评估样本量为36例,需更大规模研究确认疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRASG12D inhibitor that inhibits proliferation of KRASG12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune checkpoint blockade (ICB). In a phase Ia study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non-small cell lung cancer (NSCLC), the objective response rate (ORR; unconfirmed) was 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC), the ORR (unconfirmed) was 33.33% in the 1,000- to 1,200-mg cohort. This study supports the clinical potential of RNK08954 in patients with KRASG12D mutation either as a single agent or in combination. SIGNIFICANCE: RNK08954 is potentially the first orally bioavailable KRASG12D inhibitor, distinguished by unique PK properties, preclinical efficacy, preliminary clinical activity with encouraging results in patients with NSCLC and PDAC, and synergistic potential with ICB. RNK08954 may address a critical unmet need by targeting the most prevalent KRAS mutation across solid tumors.
引用
- Xie L, Xu C, Si H, et al. Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer Discov. 2026. PMID: 41557983. doi:10.1158/2159-8290.CD-25-1346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。